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Abstract
Background/Aim. Ligation of a Toll-like receptor (TLR) by
specific TLR agonists is a powerful tool for maturation in-
duction of monocyte-derived dendritic cells (MoDCs). Stud-
ies so far have shown that the treatment of dendritic cells
(DCs) with a TLR3 ligand, polyinosinic-polycytidylic acid
[Poly(I:C)], may be an appropriate activation agent for ob-
taining mature MoDCs, competent to prime effective im-
mune responses. However, little is known about how subse-
quent interaction of MoDCs with T cell-derived stimuli, such
as CD40 or interferon-γ (IFN-γ), modulates MoDC func-
tions. Therefore, this problem was the main objective of this
study. Methods. Immature MoDCs were prepared by culti-
vation of monocytes from peripheral blood mononuclear
cells with granulocyte macrophage-colony stimulating factor
(GM-CSF) and interleukin (IL)-4 for 5 days. After that, matu-
ration was induced by the treatment of these cells with
Poly(I:C) for 2 days. At day 6, immature MoDCs and
Poly(I:C)-activated MoDCs were incubated either with CD40
ligand (L)-transfected J558 cells or IFN-γ for additional 24
hours. Cytokine production was measured by ELISA and
FlowCytomix Human T helper Th1/Th2 11plex. Allostimu-
latory capability of MoDCs was tested using an allogeneic
mixed leukocyte reaction (MLR) assay. Results. Immature
MoDCs showed a moderate potential for stimulation of pro-
liferation of CD4+ T cells, which was enhanced by the treat-
ment with Poly(I:C). Ligation of CD40 or treatment with
IFN-γ of immature or Poly(I:C)-treated MoDCs significantly
up-regulated their allostimulatory activity. MoDCs matured in
the presence of Poly(I:C) up-regulated the production of IL-
12 and IL-10, which was followed by increased levels of IFN-
γ and decreased levels of IL-5 in co-cultures with allogeneic
CD4+ T cells. Ligation of CD40 on immature MoDCs up-
regulated the production of IL-12 and IL-23 which was ac-
companied by increased secretion of IFN-γ in co-culture.
Stimulation of CD40 on Poly(I:C)-treated MoDCs signifi-
cantly enhanced the production of IL-12, IL-23 and IL-10.
However, such treated MoDCs decreased the production of
IFN-γ and IL-10 and up-regulated the secretion of IL-17.
Immature MoDCs treated with IFN-γ up-regulated IL-12,
but lowered the production of IL-5 and IL-17 by CD4+ T
cells. Treatment of Poly(I:C)-activated MoDCs with IFN-γ
down-regulated the production of IL-12 and up-regulated IL-
10 by these cells and increased/decreased the levels of IL-10/
IFN-γ, respectively, in co-culture with CD4+ T cells. Conclu-
sion. Treatment with Poly(I:C) or ligation of CD40 on im-
mature MoDCs induces maturation of these cells into a phe-
notype that supports Th1 response. Activation of CD40 on
Poly(I:C)-treated MoDCs shifts the immune response to-
wards Th17. Treatment of immature MoDCs with IFN-γ
down-regulated Th2 and Th17 responses. However, addition
of IFN-γ to Poly(I:C)-activated MoDCs down-regulated Th1
response and promote T regulatory mechanisms. Each of
these results may have functional and therapeutic implica-
tions.
Key words:
dendritic cells; CD40 ligand; interferon-gamma;
poly I-C.
Apstrakt
Uvod/Cilj. Poliinosinsko-policitidilinska kiselina
[Polyinosinic-polycytidylic acid – Poli (I:C)] stimuliše funkcional-
no i fenotipsko sazrevanje dendritičnih ćelija (DC). Među-
tim, malo je podataka o modulaciji funkcije DC tokom inte-
rakcije sa T-limfocitima posredovanoj receptorom CD40 i
interferonom-γ (IFN-γ), što je bio cilj ovog istraživanja.Strana 302 VOJNOSANITETSKI PREGLED Volumen 68, Broj 4
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Metode. Nezrele DC dobijene su kultivacijom monocita
(Mo) iz periferne krvi u prisustvu faktora stimulacije granu-
locitno-makrofagnih kolonija (Granulocyte-Macrophage Colony-
Stimulating Factor – GM-CSF) i interleukina (IL)-4 tokom pet
dana. Sazrevanje je indukovano dvodnevnom inkubacijom
MoDC sa Poli(I:C). Poslednja 24 časa, nezrele i zrele MoDC
kultivisane su sa ćelijama J558 koje su transfektovane ligan-
dom CD40 ili u prisustvu IFN-γ. Produkcija citokina odre-
đivana je ELISA metodom, a alostimulatorna sposobnost u
mešanoj leukocitnoj kulturi. Rezultati. Stimulacija nezrelih
MoDC sa Poli(I:C) povećala je sekreciju IL-12, njihovu alo-
stimulatornu sposobnost i produkciju IFN-γ u kokulturi sa
CD4+ T limfocitima. Slični rezultati dobijeni su poveziva-
njem CD40 molekula ili tretiranjem nezrelih MoDC sa IFN-
γ. Međutim, stimulacija CD40 molekula na MoDC koje su
aktivisane sa Poli(I:C) povećala je produkciju IL-12, IL-23 i
IL-10 što je pospešilo produkciju IL-17, a snizilo produkciju
IFN-γ i IL-10 u MoDC/CD4+ kokulturi. Suprotno tome,
IFN-γ snizio je produkciju IL-12, a povećao produkciju IL-
10 od strane MoDC aktivisanih sa Poli(I:C), što je bilo po-
vezano sa sniženjem IFN-γ, a porastom nivoa IL-10 u ćelij-
skoj kokulturi. Zaključak. Poli(I:C), IFN-γ i povezivanje
CD40 molekula su aktivatori sazrevanja MoDC i stimulatori
Th1 imunog odgovora. Ligacija CD40 molekula na MoDC
aktivisanim sa Poli(I:C) usmerava u pravcu Th17, a inhibira
Th1 imuni odgovor. U istom modelu IFN-γ inhibira Th1
odgovor, a stimuliše imunoregulatorne mehanizme. Svaki
od dobijenih rezultata može imati specifične funkcijske ili
terapeutske implikacije.
Ključne reči:
ćelije, dendritične; CD40 ligand; interferon-gama;
poli I-C.
Introduction
Dendritic cells (DCs) are bone marrow-derived cells
that function as antigen-presenting cells (APCs). Immature
DCs in the periphery capture and process antigens and have
a low T cell stimulatory capability. These potent APCs ex-
press a wide variety of pattern recognition receptors
(PRRs) by which they recognize a conserved groups of
molecules, collectively known as molecular patterns (MPs).
Activation of PRRs triggers signaling pathways resulting in
phenotypic changes and functional maturation of DCs. An
important group of PRRs are Toll-like receptors (TLRs)
which are crucial proteins that link innate and adaptive
immunity 
1.
Upon encounter inflammatory cytokines, bacterial or
viral products, DCs enter a crossroad where their fate, mi-
gratory type or cytokine-producing type is determined. At
this stage DCs express costimulatory molecules, migrate to
lymphoid organs and secrete cytokines to initiate immune re-
sponses 
2, 3. Inflammatory and innate cytokines create the en-
vironment in which antigen-specific adaptive T cells expand
and differentiate into different effector CD4
+ T cells such as
T helper (Th1, Th2, Th17) and various subsets of T cells
with regulatory activities (Tregs) 
4.
Dendritic cells are also important in antitumor immu-
nity and DC-based cancer vaccines have given the encour-
aging results 
5. Human monocyte-derived DCs (MoDCs) are
currently the major source of DCs used in clinical vaccina-
tion protocols for the treatment of cancer 
6. MoDCs can be
easily prepared by plastic adherence of monocytes from pe-
ripheral blood mononuclear cells (PBMCs) and subsequent
incubation of the cells for several days in granulocyte
macrophage-colony stimulating factor (GM-CSF) and inter-
leukin (IL)-4 containing medium 
7. In vivo, human DCs have
been shown to be more efficient than immature DCs in in-
ducing specific antitumor antigen proliferative and cytotoxic
T cell responses 
8,9. Therefore, an important goal in immu-
notherapy is to identify an optimal protocol for DC matura-
tion. In vitro generated mature DCs should produce IL-12
after migration to the lymph nodes and upon subsequent
contact with T cell in order to stimulate Th1 immune re-
sponse and thus maximize clinical efficacy 
10.
Ligation of different TLRs by specific TLR agonists is
a powerful tool for induction of DC maturation both in vi-
tro and in vivo. Polyinosinic-polycytidylic acid – Poly(I:C),
a synthetic analogue of dsRNA and a TLR3 agonist, trig-
gers the maturation of MoDCs into a phenotype that
strongly supports the Th1 responses 
11. Poly(I:C)-treated
DCs show a mature phenotype with high expression of
costimulatory molecules and a maturation marker, CD83 
12.
Therefore, Poly(I:C) may be an appropriate maturation
agent for obtaining stable homogenous mature DCs that are
potentially competent to prime effective immune responses
in vivo. This is supported by the experiments showing that
such treated DCs retain the ability to secrete bioactive IL-
12 in lymph nodes which is initiated during the ex vivo
maturation step 
10.
CD40 is a cell surface receptor that belongs to the tu-
mor necrosis factor-R (TNF-R) family. Ligation of CD40 on
DCs plays an important role in an enhanced survival of these
cells, secretion of cytokines and enzymes as well as in en-
hanced tumoricidal activity and NO synthesis. CD40 ligand
(CD40L), is mainly expressed on activated CD4
+ T cells.
CD40:CD40L interaction has shown the complexity and im-
portance in T cell-dependent humoral immune responses, in
acquired cellular immune responses as well as in innate im-
munity. DC:T-cell interaction via CD40:CD40L upregulates
the expression of costimulatory and adhesion molecules on
DCs and triggers DCs to secrete IL-12 
13, l4. These data sug-
gest that ligation of CD40 on DCs may be an additional way
to enhance IL-12 production and Th1 immune response. So
far, therapies targeting CD40 have been designed to trigger
CD40 signaling and thus boost the immune response against
tumor. It should be noted that biologically relevant produc-
tion of IL-12 by DCs is not induced by CD40 engagement
alone but requires a second signal 
15 which can be provided
by other stimuli such as IFN-γ, a key Th1 cytokine.
Interferon-γ is one of the most powerful DC potentiat-
ing agent. This cytokine, which is produced by natural killer
(NK) and by Th1 cells 
16, 17 promotes specific cytotoxic im-Volumen 68, Broj 4 VOJNOSANITETSKI PREGLED Strana 303
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munity by up-regulation of costimulatory and adhesion
molecules, chemokines, antigen processing and presentation.
IFNγ is a necessary costimulus for IL-12 production in
MoDCs 
15 and this amplification may be important in stabili-
zation of the Th1 response.
Dendritic cells constatly receive multiple signals and
need to integrate them to give a response appropriate to ex-
tracellular milieu. The involved factors (TLR3 ligand,
CD40L, IFN-γ) may be of crucial importance for modulation
of ex vivo generated DCs. However, little is known whether
their combination may act sinergistically or antagonistically
on DC functions and this scientific problem was the principle
aim of this study.
Methods
Medium and reagents
Human MoDCs were cultured in RPMI 1640 medium
(ICN, Costa Mesa, CA, USA) supplemented with 2 mM  L-
glutamine, 20 μg/mL gentamicin, 50 μM 2-mercaptoethanol
(2-ME) and 10% heat inactivated fetal calf serum (FCS). Re-
combinant human IL-4 was purchased from Roche Diagnos-
tics GmbH (Mannheim, Germany). Recombinant human
GM-CSF (Leucomax, spec. activity 4.44 × 10
6 UI) was ob-
tained from Schering-Plough (Basel, Switzerland). Final
concentrations of Poly(I:C) (Sigma-Aldrich, Munich, Ger-
many) and IFN-γ (R&D Systems, Minneapolis, USA) were
25 µg/mL and 5 ng/mL, respectively. The number of
CD40L-expressing J558 cells was 1.8 x 10
6/mL.
Cell preparation and MoDC cultures
MoDCs were generated from PBMCs. Briefly, PBMCs
from buffy coats of six healthy volunteers were isolated by
density centrifugation on Lymphoprep gradient (Nycomed,
Oslo, Norway), resuspended in 5 ml of 10% FCS with 2-ME
in RPMI medium and allowed to adhere to plastic flasks.
After 2 h at 37°C, non-adherent cells were removed and ad-
herent cells were cultured in 5 ml of control medium con-
taining GM-CSF (100 ng/mL) and IL-4 (20 ng/mL). At day
3, 2.5 mL of medium was removed and replaced by the same
volume of fresh medium containing GM-CSF and IL-4. Af-
ter 6 days MoDCs were replated (5 x 10
5 cells/mL) in me-
dium with a GM-CSF/IL-4 and Poly(I:C). At day 7, half of
each of these cultures were incubated with J558 cells or with
IFN-γ for additional 24 hours. After 8 days, cell-free super-
natants were collected and stored at − 20°C for the subse-
quent determination of cytokine levels.
Allogeneic T-cell activation
The ability of T cells to proliferate was tested in an al-
logeneic mixed leukocyte reaction (MLR). CD4
+ T cells
were used as responders in MLR, after their isolation from
PBMCs using immunomagnetic sorting with CD4
+ isolation
kits (MACS technology, Myltenyi Biotec, Bergish Gladbach,
Germany) following instructions of the manufacturer. After
loading the cell suspension onto a column placed in the mag-
netic field of a MACS Separator, unlabeled cells run through
and this cell fraction consists mainly of the CD4
+ T-cell sub-
set as determined by flow cytometry using an anti-CD4 FITC
(Serotec, Oxford, UK).
Purified CD4
+ T cells (1 × 10
5 cells/well) were culti-
vated for 5 days with different numbers of allogeneic
MoDCs in complete RPMI medium with 10% FCS in 96-
well round-bottomed cell culture plates. Different DC: T
cells ratios were used. To assess cell proliferation, cells were
pulsed with [
3H]-thymidine for the last 18 h (1  μCi/well,
Amersham, Books, UK). Labeled cells were harvested onto
glass fiber filters and the incorporation of the radionuclide
into DNA was further measured by β-scintillation counting
(LKB-1219 Rackbeta, Finland). Results were expressed as
count per minute (cpm) ± SD of triplicates.
Cytokine assays
After 8 days MoDCs were treated with PMA (20
ng/mL) and ionomycin (500 ng/mL) for 8 hours to stimulate
excretion of the synthesized cytokines. A similar procedure
was used for stimulation of MoDC/CD4
+ T cell coculture
after a 5 day incubation period. Cells were harvested, centri-
fugated and cell-free supernatants were collected and stored
at − 20°C for the subsequent determination of cytokine lev-
els. The levels of IL-12p70, IL-23, IL-17 and IL-10 were
measured by sandwich ELISA assays from R&D Systems
(Minneapolis, USA), following the manufacturer's instruc-
tions. The leveles of IFN-γ and IL-5 cytokines were evalu-
ated using FlowCytomix Human Th1/Th2 11plex Kit from
Bender MedSystems (Vienna, Austria).
Statistical analysis
Data were analyzed for significant differences using
Student`s paired t-test (p < 0.05 was considered statistically
significant).
Results
Effects of CD40 ligation and IFN-γ treatment on the
cytokine production by MoDCs
Immature MoDCs were generated by incubating mono-
cytes with GM-CSF and IL-4 for 5 days. After that, matura-
tion was induced by the treatment of these cells with
Poly(I:C) for 2 days. At day 6 immature MoDCs and MoDCs
induced to mature with Poly(I:C) were incubated either with
CD40L-transfected J558 cells or IFN-γ for additional 24
hours. The levels of IL-12, IL-23 and IL-10 were detected in
culture supernantans.
The results presented in Figure 1 show that immature
MoDCs produced a very small quantity of all three cytoki-
nes. Poly(I:C) treatment significantly enhanced the produc-
tion of IL-12 and IL-10, whereas the production of IL-23
was not significantly changed. Ligation of CD40 on im-
mature DCs was followed by up-regulation of IL-12 and
IL-23. However, such treatment of Poly(I:C)-stimulated
MoDCs resulted in about 2-fold, 20-fold and 3-fold in-
crease in the production of IL-12, IL-23 and IL-10, respec-
tively. The addition of IFN-γ to immature MoDCs exerted
similar stimulatory effect on IL-12 production, as Poly(I:C)
did. No significant effect was observed regarding IL-23 andStrana 304 VOJNOSANITETSKI PREGLED Volumen 68, Broj 4
Dragičević A, et al. Vojnosanit Pregl 2011; 68(4): 301–308.
IL-10 production. However, the addition of IFN-γ to the
cultures of Poly(I:C)-treated MoDCs down-regulated the
production of IL-12 and subsequently up-regulated (7-fold
increase) the production of IL-10.
Effects of CD40 ligation and IFN-γ treatment on the
allostimulatory activity of MoDCs
The influence of CD40 ligation and IFN-γ on the al-
lostimulatory potential of immature and Poly(I:C)-treated
MoDCs was examined in a MLR, where allogeneic CD4
+ T-
cells were used as responders. The results are presented in
Figure 2.
Immature MoDCs showed a moderate potential for
stimulation of CD4
+ T-cell proliferation, which progres-
sively decreased with lowering the number of DCs as
stimulators. MoDCs matured in the presence of Poly(I:C)
enhanced the allostimulatory activity of MoDCs at the
highest (1 : 10) DC:CD4
+ T-cells ratio. Ligation of CD40
on immature MoDCs or IFN-γ treatment of these cells was
followed by significant up-regulation in their allostimula-
tory activity. Such treatment of Poly(I:C)-activated MoDCs
additionally enhanced the proliferation of allogeneic CD4
+
T-cells.
Fig. 1 - Cytokine production by immature human monocyte-derived dendritic cells (MoDCs) and polynosinic-polycytidylic
acid – Poly(I:C)-treated MoDCs activated by CD40 ligation and interferon (IFN)-γ
Supernatants of immature and Poly(I:C)-treated MoDCs challenged with CD40L-transfected J558 cells or IFN-γ
were collected and processed to determination of cytokine levels using sandwich ELISA assays.
Data represent mean values of six different experiments ± standard deviations (six donors).
Treatment: 1- control; 2- +CD40L; 3- +IFN-γ
*p < 0.05, ***p < 0.005 compared with immature MoDCs
ΔΔΔp < 0.005 compared with Poly(I:C)-treated MoDCs
Fig. 2 - Allostimulatory activity of immature human monocyte-derived dendritic cells (MoDCs) and polynosinic-
polycytidylic acid – Poly(I:C)-treated MoDCs stimulated with CD40L-transfected J558 cells and interferon (IFN)-γ
The ability of CD4
+ T cells to proliferate was tested in allogeneic mixed leukocyte reaction. Different rations of MoDC/CD4
+ T cells were used (a- 1:10;
b- 1:20; c- 1:40; d- 1:80). After five days of culture cells were pulsed with [H]
3-thymidine (1 µCi/well) for the last 18 h. Incorporation of the radionuclide
into DNA was measured by β-scintillation counting.
Data represent the mean value of triplicates ± standard deviations.
Treatment: 1- control; 2- +CD40L; 3- +IFN-γ.
*p < 0.05, ***p < 0.005 compared with control immature MoDCs
Δp < 0.05,  
ΔΔΔ p < 0.005 compared with control Poly(I:C)-treated MoDCsVolumen 68, Broj 4 VOJNOSANITETSKI PREGLED Strana 305
Dragičević A, et al. Vojnosanit Pregl 2011; 68(4): 301–308.
Effects of CD40 ligation and IFN-γ treatment on the Th
polarization capability of MoDCs
The effect of MoDCs on the polarization of Th immune
responses was measured by production of cytokines in
DC/CD4
+ T-cell co-cultures.
As shown in Figure 3 treatment of MoDCs with
Poly(I:C) up-regulated the production of Th1 cytokine
(IFN-γ), and down-regulated the production of Th2 cyto-
kine (IL-5), while the levels of IL-17 and IL-10 were not
changed. Treatment of immature MoDCs with CD40L-
transfected cells exerted similar effect on cytokine produc-
tion as Poly(I:C) did, except that the production of IL-5
was not significantly changed. In contrast, ligation of CD40
on Poly(I:C)-treated DCs enhanced Th17 response and
down-regulated Th1 response and production of IL-10. The
addition of IFN-γ to immature MoDCs showed no signifi-
cant effect on the production of IFN-γ, but lowered the
production of IL-17 and IL-5. IFN-γ treatment of MoDCs,
matured in the presence of Poly(I:C), significantly en-
hanced the levels of IL-10 and decreased production of
IFN-γ, whereas the secretion of IL-17 and IL-5 was not
significantly modulated.
Discussion
Dendritic cells are professional APCs with an unique
ability to prime naive T cells upon antigen presentation,
regulate the type of T cell–mediated immune response, but
also to induce immunological tolerance 
18. In our study we
generated DCs in vitro from peripheral blood monocytes
with GM-CSF and IL-4. It has been confirmed, similarly as
in our previous study 
19 and numerous other publica-
tions 
10, 12, 20, 21  that such MoDCs are immature, triggered
moderate allogeneic T cell response in MLR and produced
low levels of IL-12 and IL-23, dominant Th1 and Th17 polar-
izing cytokines, respectively. Such characteristics are in accor-
dance with the knowledge that the capacity of immature DCs
to stimulate the immune response is rather weak and thus lim-
its their clinical efficacy, especially as tumor vaccines 
22.
Poly(I:C) is a synthetic analog of double-stranded RNA
that binds to TLR3, a PRR highly expressed in immature
MoDCs 
23. This TLR3 agonist behaves like MP and upon
binding to TLR3 signals the presence of infectious agent,
followed by activation of DCs and induction of protection to
viral cytopathic effects 
11. Activation of DCs leads to induc-
tion of inflammatory cytokines and activation of IFN-β pro-
moter, NF-κB and MAP kinases through engagement of the
TRIF adaptor protein that cause DCs to mature 
24, 25. It is
known that Poly(I:C) induces phenotypic maturation of
MoDCs by up-regulation of co-stimulatory molecules
(CD80, CD86 and CD40), and maturation marker,
CD83 
10, 12. This could be a dominant mechanism of in-
creased allostimulatory activity of Poly(I:C)-treated MoDCs
in our experiments. Poly(I:C) is also a very potent stimulator
of IL-12 production and subsequent activator of the Th1 im-
mune response both in vitro and in vivo, the properties desir-
able for induction of anti-tumor immunity 
26. This is con-
firmed in our present study, too. Therefore, Poly(I:C) may be
an appropriate maturation agent for obtaining stable ho-
mogenous mature DCs that are potentially competent to
prime effective immune responses in vivo. This is also sup-
ported by the experiments showing that Poly(I:C)-treated
DCs retain the ability to secrete bioactive IL-12 in lymph
Fig. 3 - Polarization of Th immune response by immature human monocyte-derived dendritic cells (MoDCs) and
polynosinic-polycytidylic acid – Poly(I:C)-treated MoDCs activated with CD40L-transfected cells and interferon  (IFN)-γ
Production of cytokines in MoDC/CD4
+ T-cell cocultures was measured using sandwich ELISA assays and FlowCytomix Human Th1/Th2 11plex. Data
represent mean values of three experiments ± standard deviations (three donors). Similar differences between groups were obtained with three other do-
nors. However, the levels of all cytokines in these cultures were significantly lower  (data not shown).
Treatment: 1- control; 2- +CD40L; 3- +IFN-γ.
*p < 0.05, *** p <0.005 compared with control immature MoDCs
ΔΔΔp < 0.005 compared with control Poly(I:C)-treated MoDCsStrana 306 VOJNOSANITETSKI PREGLED Volumen 68, Broj 4
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nodes which is initiated during the ex vivo maturation step 
10.
We also showed that Poly(I:C)-treated MoDCs down-
regulated the Th2 immune response, whereas the Th17 im-
mune response was not significantly changed. Down-
regulation of Th2 immune response is in agreement with the
current concept of reciprocal regulation of Th1/Th2 balance 
27.
Ligation of CD40 on DCs plays an important role in
maturation and functional modulation of these cells 
28, 29. We
used a CD40L-transfected cell line to simulate CD40:CD40L
bidirectional crosstalk between DCs and T cells that provides
reciprocal regulation of both lymphocytes and DCs 
28, 29. We
showed that ligation of CD40 on immature or Poly(I:C)-
treated MoDCs significantly up-regulated their allostimula-
tory activity, most probably as a consequence of increased
expression of adhesion and co-stimulatory molecules, such
as ICAM-1, HLA-DQ, CD80 and CD86 
30. It has already
been shown that the engagement of CD40 on immature
MoDCs as a single signal induces high levels of Th1 polar-
izing cytokine IL-12 
15 and subsequent production of IFN-γ.
We confirmed such results in our study. Moreover, we dem-
onstrated that ligation of CD40 on immature MoDCs was
followed by an increased production of IL-23 and IL-17, a
phenomenon that has not been described so far. The produc-
tion of IL-17 was additionally enhanced following ligation
by CD40 on Poly(I:C)-treated MoDCs. IL-17 is a signature
cytokine of the Th17 subset of CD4
+ T cells, whose expan-
sion and maturation is promoted by IL-23 
31. The Th17 im-
mune response was potentiated after ligation of CD40 on
Poly(I:C)-treated MoDCs, but this was followed by down-
regulation of Th1 immune response.
Th1 cells were considered as the most important CD+ T
cell subset for generating antitumor immunity because of
their potential to enhance cytotoxic function of CD8
+ cells by
producing IFN-γ, as a key activating factor. Recent publica-
tions shed new light on potential benefits of Th17 cells in
rejection of tumors 
32, 33. Athough first it was considered that
the effects of Th17 cells were dependent on IFN-γ and inde-
pendent of IL-17 and IL-23, due to conversion of Th17 to
Th1 
32, the protective function of Th17 cells, with maintained
cytokine expression profile, against tumors have been con-
firmed 
33. The properties of Th17 cells, such as the ability to
enhance inflammatory responses and to increase antigen
presentation by DCs, promotion of leukocyte homing to tu-
mors, facilitation of CD8
+ T cell priming and effector differ-
entiation offer new possibilities for developing the Th17 cell-
based therapy for tumors. Regarding the results of our study
which are consistent with new insights of tumor immuno-
therapy, Poly(I:C) together with CD40 ligation generates de-
sirable CD4
+ T cell subsets with suitable cytokine mileu for
the treatment of tumors. However, such hypothesis needs
further testings in vivo because we showed that signaling
through CD40 on Poly(I:C)-treated MoDCs decreased the
Th1 immune response. At the moment it is not known
whether such balance between Th1 and Th17 immune re-
sponse is optimal for antitumor immune response or not. It is
known that the Th1 type of immune response could be harm-
ful if exaggerated 
34 and thus CD40 signaling could be pro-
tective and immunomodulatory.
Interferon-γ is classified as type II IFN in accordance
with its receptor specificity and sequence homology 
35. IFNs
were initially described as agents that interfere with viral
replication 
36. IFN-γ is produced by NK cells and possibly by
APCs during the early course of infection, while T lympho-
cytes became a major source of this cytokine in the adaptive
immune response 
37. Cytokine increases antigen processing,
presentation and APC costimulatory molecules 
35. We
showed in this work that the treatment of immature or
Poly(I:C)-activated MoDCs with IFN-γ also enhanced the
proliferative activity of allogeneic CD4
+ T cells. The al-
lostimulatory potential of MoDCs decreased by lowering the
DC:CD4
+ T cell ratio. At higher ratios MoDCs showed lesser
proliferative capability. One explanation could be that
stimulatory effects of costimulatory and adhesion molecules
and suitable levels of IL-12 are abrogated by low numbers of
producing cells.
A significant finding of this study was related to the
dual role of IFN-γ on IL-12 production: stimulation by im-
mature MoDCs; suppression by Poly(I:C)-treated MoDCs.
The increased production of IL-12 was followed by in-
creased IFN-γ production and down-regulation of IL-5 and
IL-17 production by CD4
+  T cells in co-culture. Up-
regulation of IL-12 by immature MoDCs is in agreement
with previous results 
17. The produced IL-12 attracts and ac-
tivates T cells and NK cells to produce IFN-γ 
14 which, in
return, stimulate further production of IL-12 by amplifying
loop. Down-regulation of IL-5 production could be explained
by reciprocal regulation of Th1 and Th2 immune response 
27
and by direct inhibitory effect of IFN-γ on the growth of Th2
cells 
35. The reason why IFN-γ-treated MoDCs inhibited IL-
17 production without significant changes of IL-23 produc-
tion is not clear. Since IL-23 predominantly acts on already
differentiated Th17 cell subset 
31, it is possible that IFN-γ-
treated MoDCs inhibited the differentiation of Th17
+ cells by
modulating the production of Th17 differentiation cytokines
such as TGF-β, IL-1β, IL-6 and IL-21 
38. Therefore, this hy-
pothesis should be tested in the next experiment.
The inhibition of IL-12 production and stimulation of
IL-10 production by IFN-γ- and Poly(I:C)-treated MoDCs is
an important finding which could be relevant for down-
regulation of Th1 immune response and promotion of an IL-
10-mediated immunoregulatory milieu. It is not completely
clear whether IFN-γ primarily acts on down-regulation of IL-
12 by Poly(I:C)-activated MoDCs or on up-regulation of IL-
10 production. It is known that IL-10 is a potent anti-
inflammatory and immunosuppresive cytokine that inhibits
the production of IL-12 by MoDCs 
39. Therefore, IL-10 is a
very important cytokine for self-limiting Th1 cell-mediated
immunopathology in conditions of strong inflammatory
stimuli 
40, 41.
Recently it has been shown that IFN-γ, beside amplifying
production of pro-inflammatory cytokines during activation of
DCs, also triggers an immunosuppressive enzyme indoleamine
2,3-dioxygenase (IDO) activity in DCs 
42. It is known that
IDO
+ DCs exert immunoregulatory potential which is impor-
tant for down-regulation of the immune response 
43. In addi-
tion, cytokine can also induce the development of adaptiveVolumen 68, Broj 4 VOJNOSANITETSKI PREGLED Strana 307
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regulatory T cells 
42. Cumulatively, our results support the
concept that IFN-γ, as a dominant Th1 effector cytokine, with
the pro-inflammatory properties could be also an important
down-regulator of strong immune response.
Conclusion
Treatment with Poly(I:C) or ligation of CD40 on im-
mature MoDCs induced maturation of these cells into a phe-
notype that supports Th1 response. Activation of CD40 on
Poly(I:C)-treated MoDCs shifted the immune response to-
wards Th17. Treatment of immature MoDCs with IFN-γ
down-regulated Th2 and Th17 responses. However, addition
of IFN-γ to Poly(I:C)-treated MoDCs down-regulated Th1
response and promoted immunoregulatory mechanisms by
induction of IL-10, thus limiting the exaggerated and poten-
tially harmful immune response.
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